Infinimmune Launches GLIMPSE-1 AI Model Trained Exclusively on Human Antibody Sequences for Advanced Therapeutic Engineering
ALAMEDA, Calif.--(BUSINESS WIRE)--Jun 12, 2025--
Infinimmune, a biotechnology company pioneering human-first antibody discovery and design, today announced the launch of GLIMPSE-1, a protein language model trained solely on native human antibody sequences. Developed using millions of paired heavy and light chains from human memory B cells, GLIMPSE-1 represents a new paradigm for therapeutic antibody engineering that applies the design principles of the human adaptive immune system.
Infinimmune published results in a new bioRxiv preprint, demonstrating that GLIMPSE-1 can humanize clinical antibodies, engineer for affinity and developability parameters, and generate highly divergent functional variants, all through in silico design guided by the biology of the human adaptive immune system.
'Fully human antibodies carry the evolutionary fingerprints of the human immune system, optimized over millions of years,' said Wyatt McDonnell, Ph.D., Co-Founder and CEO, Infinimmune. 'With GLIMPSE-1, we can decode and encode that logic directly from immune repertoires to discover and design better, safer biologics from day one. This approach complements the FDA's recent focus on assessing human-relevant methods for therapeutic development, which could ultimately benefit patients through more comprehensive safety assessment. We believe models like GLIMPSE-1 will remain essential in the discovery and development of modern antibody medicines.'
GLIMPSE-1 was developed as a core component of Infinimmune's therapeutic development capabilities, strengthening the company's pipeline of antibody drug candidates. The model was trained using a large, diverse dataset with proprietary sequences from Infinimmune's Complete Human® and Anthrobody® technologies, which source antibodies directly from native human repertoires, allowing it to learn the biological and functional constraints of human immunity.
Key results from the preprint include:
GLIMPSE-1 operates entirely in human antibody sequence space, predicting viable antibody variants without 3D structure modeling, energy calculations, or experimental screening beforehand. The resulting antibodies maintain essential functional properties and characteristics consistent with clinically approved monoclonal antibodies, all guided by patterns learned from human immune systems.
The development of GLIMPSE-1 aligns with recent FDA initiatives exploring human-relevant methodologies for therapeutic development. The FDA's roadmap for integrating New Approach Methodologies (NAMs) identifies monoclonal antibodies as an initial focus area, creating an environment where human-first models like GLIMPSE-1 may provide valuable complementary insights.
Infinimmune has successfully integrated GLIMPSE-1 into its therapeutic antibody development pipeline, where the model has significantly contributed to the engineering and optimization of the company's lead programs. The company is currently exploring strategic partnerships with pharmaceutical and biotechnology companies to apply GLIMPSE-1's capabilities to partner's therapeutic programs.
About Infinimmune
Infinimmune is a biotechnology company pioneering a novel approach to antibody drug discovery and development. Founded by a world-class, multidisciplinary team of scientists and technologists, Infinimmune is reinventing antibody discovery with an end-to-end platform to deliver antibody drugs derived directly from the human immune system. These truly human antibodies are designed to drug new and existing targets with improved safety and efficacy. Infinimmune is building its own pipeline of drug candidates and partnering with pharmaceutical companies to advance their antibody programs, fill their pipelines, and reach new patients and new indications. To learn more, visit infinimmune.com and follow us on LinkedIn and @infinimmune.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250611619715/en/
CONTACT: Media
Kimberly Ha
KKH Advisors
917-291-5744
[email protected]
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: RESEARCH TECHNOLOGY GENETICS SOFTWARE BIOTECHNOLOGY PHARMACEUTICAL HEALTH SCIENCE ARTIFICIAL INTELLIGENCE OTHER SCIENCE
SOURCE: Infinimmune
Copyright Business Wire 2025.
PUB: 06/12/2025 08:07 AM/DISC: 06/12/2025 08:05 AM
http://www.businesswire.com/news/home/20250611619715/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
28 minutes ago
- Business Insider
KalVista says FDA will not meet PDUFA goal date for Sebetralstat NDA
KalVista (KALV) Pharmaceuticals nnounced that the U.S. Food and Drug Administration has notified the company that it will not meet the PDUFA goal date for the New Drug Application for sebetralstat, the company's investigational oral on-demand treatment for hereditary angioedema. The FDA notified the company on June 13, 2025, that the previously disclosed June 17, 2025 PDUFA goal date will not be met due to heavy workload and limited resources. The FDA indicated that it expects to deliver a decision within approximately four weeks. The FDA has not requested additional data or studies and has not raised any concerns regarding the safety, efficacy or approvability of sebetralstat. KalVista has addressed all prior information requests in a timely manner, and the company believes the only remaining item under FDA review is the finalization of the labelling. 'We are disappointed by this delay, most importantly because we know how much people living with HAE are looking forward to an oral on-demand option to treat their HAE attacks,' said Ben Palleiko, CEO of KalVista. 'At the same time, we remain confident in the near-term approval of sebetralstat. We are continuing to work closely with the FDA to support the completion of their review. Our commitment to bringing this important therapy to people living with HAE remains unwavering.'
Associated Press
an hour ago
- Associated Press
ROCKET ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Rocket Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. ('Rocket' or the 'Company') (NASDAQ:RCKT) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired Rocket securities between February 27, 2025 to May 26, 2025, both dates inclusive (the 'Class Period'). Investors have until August 11, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Click here to participate in the action. According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of RP-A501's safety and clinical trial protocol; notably, that Rocket knew Serious Adverse Events (SAEs), including death of participants enrolled in the study, were a risk. In particular, Rocket amended the trial's protocol to introduce a novel immunomodulatory agent to the pretreatment regimen without providing this critical update to shareholders. Such statements absent these material facts caused Plaintiff and other shareholders to purchase Rocket's securities at artificially inflated prices. On May 27, 2025, Rocket announced that the FDA placed a clinical hold on the RP-A501 Phase 2 pivotal study after at least one patient suffered a Serious Adverse Event (SAE), ultimately, death, while enrolled in the study following a substantive amendment to the protocol that the Company failed to disclose to investors at the time management made the revision. In fact, Rocket stated that, while the patient was dosed in May, the decision to amend the protocol was made 'several months' earlier. Despite this, Rocket made no attempt to alert investors or the public to the change until after the SAE occurred. Following this news, the price of Rocket's common stock declined dramatically. From a closing market price of $6.27 per share on May 23, 2025, Rocket's stock price fell to $2.33 per share on May 27, 2025, a decline of about 37% in the span of just a single trading day. If you purchased or otherwise acquired Rocket shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X. Contact Information: Bragar Eagel & Squire, P.C. Brandon Walker, Esq. Marion Passmore, Esq. (212) 355-4648
Yahoo
2 hours ago
- Yahoo
Sombre Fundamentals Suggest General Mills Stock (GIS) is Stuck in a Value Trap
Not so long ago, General Mills (GIS) stock was synonymous with safety, defensiveness, and stability. The company consistently delivered results in line with market expectations, rewarding shareholders with a generous and growing dividend. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter The snacking category, once an exception among packaged food groups, seemed immune to changing eating habits and the rise of private-label brands. But things have taken a turn for the worse. Cereal and snack bar consumption has declined sharply due to growing structural headwinds, resulting in a contraction of General Mills' business. What remains solid, however, is the company's ability to generate value for shareholders above its cost of capital, which in theory still makes General Mills a defensive stock. Valuations at current levels also look attractive, offering some margin of safety. The problem is that the sustainability of these strengths is in question. When secular headwinds are at play, it doesn't matter much if fundamentals suggest a cushion or if valuations appear cheap—the stock is likely to continue drifting downward over time. That said, I see this as a potential value trap for investors hoping to be heroes with General Mills stock. For that reason, I hold a neutral view on GIS. U.S. consumers have been gradually changing their eating habits—and that's not just an opinion, it's a fact. The packaged foods sector has seen a decline in demand for snacks in recent years. A big part of this comes from the rapid rise in GLP-1 weight loss drugs and a new generation that's increasingly avoiding 'bad foods' in favor of a healthier lifestyle. Recent 2024 data shows that around 12% of American adults report having used a GLP-1 drug, with 6% currently using one. Some studies suggest that GLP-1 users significantly reduce their grocery store purchases by 6%, with a 11% drop in snack sales in the six months following adoption. This shift is already reflected in the financial results of packaged food companies, such as General Mills. Over the past three years, General Mills' revenue has grown at a CAGR of just 1.8%. While operating margins improved at a 4.9% compound annual growth rate (CAGR), free cash flow declined at an 8.7% CAGR, which is a concerning trend. In addition to these broad changes in consumer behavior, General Mills has been facing weak U.S. consumption trends due to market share losses in key categories, particularly to private-label brands from retailers such as Costco (COST) and Walmart (WMT). In its most recent earnings report, net sales totaled $4.8 billion, a 5% decline year over year, and fell short of analyst expectations. North American retail sales declined 7%, with a 6% drop in sales volume. Alongside softer demand, temporary pressures also played a role, including lower volumes in snacks and dry pet food. The pet segment declined 3% year over year, while international sales fell 4%, primarily due to foreign exchange headwinds and weaker results in key markets such as China and Brazil. As a result, General Mills revised its guidance for fiscal year 2025. The company now expects organic net sales to decline between 1.5% and 2%, compared to a previous forecast of flat to slightly positive growth (up to 1%). While General Mills' stock performance may appear underwhelming—hovering near the same levels it traded at over a decade ago—there are still compelling elements to its investment case. Despite a growth narrative that appears not just stalled but potentially in decline, the company continues to deliver strong returns on invested capital (ROIC). Over the past twelve months, General Mills generated $2.93 billion in NOPAT against $22.9 billion in invested capital, resulting in an ROIC of 12.8%. That figure aligns well with industry peers like Nestlé (NSRGY), Mondelez (MDLZ), and Kellogg's (KLG), and it comfortably exceeds the company's estimated cost of capital, highlighting efficient capital deployment even in a slow-growth environment. Assuming a cost of equity of 7.5% (given GIS's low beta and 10-year Treasury yields around 4.5%), and a 30% debt weighting, General Mills' weighted average cost of capital (WACC) would land around 6.8%. In other words, despite the recent headwinds, the company continues to create value for shareholders and allocate capital efficiently. That shows up in its dividend policy as well. General Mills currently offers a dividend yield of 4.4%, which is almost on par with the risk-free rate, all while maintaining a payout ratio of just 53%. Beyond General Mills' ability to generate returns above its cost of capital, the stock also appears attractively priced based on valuation. One particularly useful—and often underappreciated—metric for evaluating mature, capital-intensive companies like those in the consumer packaged goods sector is earnings yield, calculated as operating income divided by enterprise value. Over the past twelve months, General Mills reported $3.6 billion in operating income (EBIT) against an enterprise value of $43.5 billion, resulting in an earnings yield of 8.4%. Compared to a weighted average cost of capital (WACC) of 6.8%, this positive spread suggests the company is generating real value for shareholders—a potentially encouraging sign for long-term investors. However, the reliability of earnings yield as a valuation signal rests on the assumption that earnings will remain stable or improve. In General Mills' case, that assumption is under strain. The company recently lowered its fiscal 2025 guidance, now forecasting a 7% to 8% decline in adjusted operating profit, nearly twice the size of its earlier projections. In short, while the current valuation offers a degree of margin of safety, the growing uncertainty around future profitability raises meaningful concerns and tempers a more bullish outlook. Analyst sentiment on General Mills (GIS) remains mixed. Of the 13 analysts covering the stock, only one holds a bullish rating, ten are neutral, and one is bearish. The consensus stock price target for GIS stock is $57.67, representing an upside of approximately 6.7% over the coming year. General Mills checks many of the boxes for a classic value investment, consistently generating returns above its cost of capital while trading at what appears to be an attractive valuation. However, the company is contending with mounting structural headwinds—including evolving consumer eating habits, the rise of GLP-1 drugs, shifting retail dynamics, and increased competition from private-label brands. These challenges cast doubt on the long-term sustainability of its value creation, despite current metrics remaining solid. Given these concerns, General Mills currently leans more toward a value trap than a compelling value opportunity. Disclaimer & DisclosureReport an Issue Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
